GEMMABio Doses First Patient in Phase 1/2 Trial of Next-Generation Gene Therapy GB221 for Spinal Muscular Atrophy Type 1
核心洞察
GEMMABio (搜索) has dosed the first patient in the CHARISMA Phase 1/2 clinical trial of GB221, a next-generation gene therapy for spinal muscular atrophy type 1 (搜索) (SMA1 (搜索)).
GB221 represents the first clinical evaluation of a gene therapy for SMA1 (搜索) delivered directly to cerebrospinal fluid via intracisterna-magna injection, using proprietary CNS platform technology.
The trial will evaluate safety, tolerability, and efficacy in pediatric participants aged two weeks to younger than twelve months, including both symptomatic and presymptomatic patients.
GEMMABio (搜索), a clinical-stage global genetic medicines company, announced that the first patient has been dosed in the Phase 1/2 CHARISMA clinical trial of GB221, an investigational next-generation gene therapy for spinal muscular atrophy type 1 (搜索) (SMA1 (搜索)). The milestone marks a significant advancement in treating one of the most severe forms of spinal muscular atrophy (搜索), which affects approximately 1 in 17,000 live births globally.
Novel Delivery Approach for SMA1 Treatment
The CHARISMA trial (NCT07070999) represents the first clinical evaluation of a next-generation gene therapy for SMA1 (搜索) delivered directly to the cerebrospinal fluid (CSF) by intracisterna-magna (ICM) injection. This approach utilizes proprietary central nervous system (CNS) platform technology licensed from the University of Pennsylvania, developed by Dr. Jim Wilson's research team.
GB221 was engineered to express a functional, codon-optimized SMN1 (搜索) gene from a modified transgene expression cassette specifically designed to reduce overexpression-related toxicities and sensory neurotoxicity. The therapy consists of an adeno-associated virus (AAV) human isolate, AAVhu68, encasing the functional SMN1 gene copy.
Trial Design and Patient Population
The Phase 1/2 study will evaluate safety, tolerability, and efficacy in pediatric participants ranging from two weeks to younger than twelve months of age. The trial design includes cohorts of both symptomatic and presymptomatic participants, addressing the critical early intervention window for SMA1 (搜索) patients.
"I would like to express our gratitude for the young child and family who were courageous in being the first to accept our investigational gene therapy for SMA1 (搜索)," said GEMMABio (搜索) CEO James M. Wilson, MD, PhD. "We appreciate our steadfast partners at Fiocruz (搜索) / Bio-Manguinhos, Brazil Ministry of Health, ANVISA (Brazil health regulatory agency), Casa dos Raros, Intrials (搜索), and the Hospital de Clínicas de Porto Alegre (搜索) medical team."
International Partnership and Clinical Operations
The trial is being conducted through a partnership between GEMMABio (搜索) and the Oswaldo Cruz Foundation (搜索) (Fiocruz (搜索)), announced in October 2024. Brazil serves as a regional hub in Latin America for GEMMABio's gene therapy programs, with Intrials (搜索), a Brazilian contract research organization, managing the clinical trials in the country.
Jonas Morales Saute, MD, PhD, a principal investigator specializing in neurology and neurogenetics at the Hospital de Clínicas de Porto Alegre (搜索), noted: "The medical team is monitoring the first patient carefully, hoping to see therapeutic benefit and progress towards developmental milestones. We are excited to leverage our experience in genetic diseases and clinical research to accelerate the development and evaluation of genetic medicines for other rare diseases."
Regulatory Recognition and Market Incentives
The U.S. FDA recently granted GB221 rare pediatric disease designation (RPDD). Upon clinical trial completion, if GB221 meets criteria for a rare pediatric disease product application and receives FDA approval, GEMMABio (搜索) will be eligible to receive a priority review voucher (PRV). The Rare Pediatric Disease Priority Review Voucher Program was renewed by the U.S. Congress in the Consolidated Appropriations Act of 2026 and will remain in effect through September 2029.
Addressing Critical Medical Need
Spinal muscular atrophy (搜索) is a progressive neurodegenerative disease affecting motor neurons in the spinal cord and adversely impacting skeletal muscles. The condition is caused by mutations in the survival motor neuron gene 1 (搜索) (SMN1 (搜索)) and follows an autosomal recessive inheritance pattern. The global incidence of all SMA types is approximately 1 in 10,000 live births.
SMA1 (搜索) represents the most severe form, with early onset and diagnosis typically occurring before 6 months of age. Untreated SMA1 patients do not survive beyond 18 months of age. These patients typically have 1-2 copies of the SMN2 (搜索) gene, which modulates disease severity.
The absence of functional SMN1 (搜索) protein in motor neurons represents the underlying pathophysiology that GB221 aims to address through direct gene replacement therapy. Progressive muscle weakness in SMA1 (搜索) patients impairs critical functions including breathing, eating, and motor development.
Fiocruz (搜索) President Mario Moreira, PhD, MPH, emphasized the broader implications: "The ongoing clinical study opens a front of action that can transform the lives of families and children who deal with the disease on a daily basis. The technology incorporation agreement also guarantees the opening of pathways for access to an innovative gene therapy for the first time in the Unified Health System."